Unknown

Dataset Information

0

Impact of APOE ?4 genotype on initial cognitive symptoms differs for Alzheimer's and Lewy body neuropathology.


ABSTRACT:

Background

APOE ?4 carrier status is known to increase odds of amnestic presentations with Alzheimer's pathology. It is unknown how APOE ?4 carrier status impacts odds of specific initial cognitive symptoms in the presence of Lewy body pathology. Here we evaluate the impact of APOE ?4 genotype on initial cognitive symptoms among those with Alzheimer's disease pathology (ADP) and Lewy-related pathology (LRP).

Methods

A retrospective cohort study of 2288 participants with neuropathology confirmed ADP or LRP in the National Alzheimer's Coordinating Center database, who had initial cognitive symptoms documented and had a Clinical Dementia Rating-Global (CDR-G) score???1 (cognitively normal, MCI, or early dementia). Unadjusted and adjusted logistic regression models taking into account age at evaluation, sex, and education examined the relationship between APOE ?4 genotype and initial symptoms (memory, executive, language visuospatial) among ADP with LRP and ADP-LRP groups.

Results

One thousand three hundred three participants met criteria for ADP alone, 90 for LRP alone, and 895 for co-existing ADP and LRP (ADP-LRP). Younger age increased odds of non-amnestic symptoms across all three groups. In the adjusted model among ADP, APOE ?4 carriers had higher odds of amnestic initial symptoms 1.5 [95% CI, 1.7-2.14, p?=?0.003] and lower odds of initial language symptoms 0.67 [95% CI, 0.47-0.96, p?=?0.03] than non-carriers. The odds for these two symptoms were not different between ADP and mixed ADP-LRP groups. Female sex and higher education increased odds of initial language symptoms in the ADP group in the adjusted model. In the unadjusted model, APOE ?4 carriers with LRP had a higher odds of visuospatial initial symptoms 21.96 [95% CI, 4.02-110.62, p?ConclusionsThe odds of specific initial cognitive symptoms differed between ADP and LRP among APOE ?4 carriers compared to non-carriers. The odds of initial amnestic symptom was higher among ADP APOE ?4 carriers and the odds of visuospatial initial symptom was higher with LRP APOE ?4 carriers. This supports the hypothesis that APOE ?4 differentially impacts initial cognitive symptoms together with underlying neuropathology.

SUBMITTER: Pillai JA 

PROVIDER: S-EPMC7825215 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Impact of APOE ε4 genotype on initial cognitive symptoms differs for Alzheimer's and Lewy body neuropathology.

Pillai Jagan A JA   Bena James J   Bonner-Jackson Aaron A   Leverenz James B JB  

Alzheimer's research & therapy 20210123 1


<h4>Background</h4>APOE ε4 carrier status is known to increase odds of amnestic presentations with Alzheimer's pathology. It is unknown how APOE ε4 carrier status impacts odds of specific initial cognitive symptoms in the presence of Lewy body pathology. Here we evaluate the impact of APOE ε4 genotype on initial cognitive symptoms among those with Alzheimer's disease pathology (ADP) and Lewy-related pathology (LRP).<h4>Methods</h4>A retrospective cohort study of 2288 participants with neuropatho  ...[more]

Similar Datasets

| S-EPMC9313121 | biostudies-literature
| S-EPMC6597983 | biostudies-literature
| S-EPMC10496176 | biostudies-literature
| S-EPMC6050144 | biostudies-literature
| S-EPMC7996001 | biostudies-literature
| S-EPMC10427737 | biostudies-literature
| S-EPMC3623699 | biostudies-literature
| S-EPMC7471113 | biostudies-literature
| S-EPMC4890824 | biostudies-other
| S-EPMC2778270 | biostudies-literature